Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2008

View Archived Issues

Novartis reviews recent highlights

New compounds for neurological disorders disclosed in recent patents

Recent patents describe new agents for endocrine-related disorders

Gilead initiates enrollment in phase III clinical trial of integrase inhibitor elvitegravir in HIV

Roche gives up rights to license voclosporin for solid organ transplant

Japanese Ministry of Health, Labor and Welfare grants approval to Ikaria's INOflo

Sunitinib under preclinical development for head and neck squamous cell carcinoma

Metronomic therapy with novel Bcl-2 inhibitor and cisplatin shows benefit in head and neck cancer

JSI-124 enhances activity of cisplatin against resistant head and neck carcinoma

Sanofi-aventis begins phase III studies with AVE-0010 for the treatment of type 2 diabetes

SkyePharma reports positive results from two phase III clinical studies of Flutiform

Merck profiles highlights of second quarter

FDA yet to make decision regarding Theravance's NDA for telavancin in cSSSI

Protherics presents update on company's activities

Hyperion completes enrollment in phase I/II clinical trial of HPN-100 vs. Buphenyl in UCD

CeNeRx to initiate phase II trial of Tyrima in depression in third quarter of 2008

Xanodyne receives approvable letter from FDA for pain treatment Zipsor

RNAi against PrPc reduces neurodegeneration and extends survival in murine prion disease

Optimer completes enrollment in phase III OPT-80 trial in C. difficile infection

Bristol-Myers Squibb and AstraZeneca submit NDA and MAA for Onglyza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...